PCRX
Pacira BioSciences, Inc.
NASDAQ: PCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$22.74
-1.77% today
Updated 2026-05-11
Market cap
$910.90M
P/E ratio
178.08
P/S ratio
1.24x
EPS (TTM)
$0.13
Dividend yield
—
52W range
$19 – $28
Volume
0.7M
WallStSmart proprietary scores
41
out of 100
Grade: D
Sell
Investment rating
4.0
Growth
C5.0
Quality
C+4.0
Profitability
C4.7
Valuation
C—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →198 stocks currently score above 75
Price targets
Analyst target
$29.29
+28.80%
12-Month target
$1.09
-95.21%
Intrinsic (DCF)
$196.10
Margin of safety
+88.92%
1 Strong Buy3 Buy2 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $22.96M — positive
+ 88.92% below intrinsic value
Risks
- Thin margins at 0.70%
- P/E 178.08x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $666.82M | $674.98M | $700.97M | $726.41M | $734.86M |
| Net income | $15.91M | $41.95M | $-99.56M | $7.03M | $2.92M |
| EPS | — | — | — | — | $0.13 |
| Free cash flow | $115.20M | $139.49M | $178.75M | $136.66M | $22.96M |
| Profit margin | 2.39% | 6.22% | -14.20% | 0.97% | 0.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-23 | CROSS, SHAWN | Sale | 12,941 | — |
| 2026-04-23 | CROSS, SHAWN | Buy | 12,941 | $16.45 |
| 2026-04-22 | CROSS, SHAWN | Sale | 1,500 | — |
Peer comparison
Smart narrative
Pacira BioSciences, Inc. trades at $22.74. representing a P/E of 178.08x trailing earnings. Our Smart Value Score of 41/100 indicates the stock is fair. TTM revenue stands at $734.86M. with profit margins at 0.70%. Our DCF model estimates intrinsic value at $196.10.
Frequently asked questions
What is Pacira BioSciences, Inc.'s stock price?
Pacira BioSciences, Inc. (PCRX) trades at $22.74.
Is Pacira BioSciences, Inc. overvalued?
Smart Value Score 41/100 (Grade D, Sell). DCF value $196.10.
What is the price target of Pacira BioSciences, Inc. (PCRX)?
The analyst target price is $29.29, representing +28.8% upside from the current price of $22.74.
What is the intrinsic value of Pacira BioSciences, Inc. (PCRX)?
Based on our DCF model, intrinsic value is $196.10, a +88.9% margin of safety versus $22.74.
What is Pacira BioSciences, Inc.'s revenue?
TTM revenue is $734.86M.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.24x
ROE0.71%
Beta0.32
50D MA$23.43
200D MA$23.68
Shares out0.04B
Float0.04B
Short ratio—
Avg volume0.7M
Performance
1 week-6.24%
1 month-2.69%
3 months+9.87%
YTD-10.55%
1 year—
3 years—
5 years—